Shortage of Actilyse (alteplase) and Actilyse Cathflo (alteplase)
Shortage of Actilyse (alteplase) and Actilyse Cathflo (alteplase)
Shortage of Actilyse (alteplase) and Actilyse Cathflo (alteplase)
Shortage of Metalyse (tenecteplase)
Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Date of authorisation: 06/11/2023, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Pioglitazone Accord, pioglitazone, Date of authorisation: 21/03/2012, Revision: 9, Status: Authorised
ICH guideline E11A on pediatric extrapolation Step 5
Seventh European Medicines Agency - Medicines for Europe annual bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 29 May 2024, 14:00 (CEST) to 29 May 2024, 16:00 (CEST)
Questions and answers relating to Grant Procedure no. EMA/GRANT/2024/02/IA - Medicines regulatory systems strengthening in Sub-Saharan Africa
Request to the CVMP for classification of a veterinary medicinal product as intended for a limited market according to Article 4(29) and for eligibility for authorisation according to Article 23 (Applications for limited markets)
Orphan designation: sargramostim Treatment of hereditary orotic aciduria, 28/06/2024 Positive
Metamizole-containing medicinal products article 107i referral - Timetable for the procedure